Elyse Stock - Dec 14, 2021 Form 4 Insider Report for Biohaven Pharmaceutical Holding Co Ltd. (BHVN)

Role
Chief Medical Officer
Signature
/s/ Jim Engelhart, Attorney-in-Fact
Stock symbol
BHVN
Transactions as of
Dec 14, 2021
Transactions value $
-$2,625,376
Form type
4
Date filed
12/16/2021, 08:04 PM
Previous filing
Nov 26, 2021
Next filing
Jan 7, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BHVN Common Shares Options Exercise $69.9K +3.36K +45.02% $20.79* 10.8K Dec 14, 2021 Direct F1
transaction BHVN Common Shares Options Exercise $38.7K +3.58K +33.03% $10.82* 14.4K Dec 14, 2021 Direct F1
transaction BHVN Common Shares Sale -$729K -6.94K -48.17% $105.02* 7.47K Dec 14, 2021 Direct F1, F2
transaction BHVN Common Shares Options Exercise $145K +7K +93.69% $20.79* 14.5K Dec 15, 2021 Direct F1
transaction BHVN Common Shares Options Exercise $161K +14.9K +103.18% $10.82* 29.4K Dec 15, 2021 Direct F1
transaction BHVN Common Shares Sale -$2.14M -20.3K -69.18% $105.43* 9.06K Dec 15, 2021 Direct F1, F3
transaction BHVN Common Shares Sale -$169K -1.59K -17.55% $106.17* 7.47K Dec 15, 2021 Direct F1, F4
holding BHVN Common Shares 2.19K Dec 14, 2021 By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BHVN Employee Stock Option (Right to Buy) Options Exercise $0 -3.36K -15.35% $0.00 18.5K Dec 14, 2021 Common Shares 3.36K $20.79 Direct F1, F5
transaction BHVN Employee Stock Option (Right to Buy) Options Exercise $0 -3.58K -19.34% $0.00 14.9K Dec 14, 2021 Common Shares 3.58K $10.82 Direct F1, F6
transaction BHVN Employee Stock Option (Right to Buy) Options Exercise $0 -7K -37.75% $0.00 11.5K Dec 15, 2021 Common Shares 7K $20.79 Direct F1, F5
transaction BHVN Employee Stock Option (Right to Buy) Options Exercise $0 -14.9K -100% $0.00* 0 Dec 15, 2021 Common Shares 14.9K $10.82 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.00 - $105.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.00 - $105.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.00 - $106.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F5 The shares underlying this option vested as to 25% of the shares on December 7, 2018, the grant date, and the remainder vested in 3 equal installments on the first, second and third anniversaries of the grant date.
F6 The shares underlying this option vested as to 25% of the shares on April 6, 2017, the grant date, and the remainder vested in 3 equal installments on the first, second and third anniversaries of the grant date